Evidence map›Paper›PMID 28456940›Full record

ArticleMolecular neurobiology2018

MPTP Mouse Model of Preclinical and Clinical Parkinson's Disease as an Instrument for Translational Medicine.

Eduard R Mingazov, Gulnara R Khakimova, Elena A Kozina, Alexei E Medvedev, Olga A Buneeva, Ara S Bazyan, Michael V Ugrumov

Abstract read
PubMed Publisher
In one paragraph

Article in Molecular neurobiology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.

0numbers the graph read from it
0cells of the map it votes in
20citing papers in PubMed
2.6field-weighted citation impact, top 10% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

20 citing papers in PubMed, 64 citations in OpenAlex.

  1. Article
  2. Article
  3. Monoamine Oxidase Inhibitors in Toxic Models of Parkinsonism.International journal of molecular sciences · 2025
    Review
  4. Article
  5. Article
  6. Review
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Review
  15. Review
  16. Review
  17. Article
  18. Article
  19. Nutrients · 2019
    Article
  20. The Ameliorative Effects of the Ethyl Acetate Extract ofOxidative medicine and cellular longevity · 2019
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 4 institutions in 1 country.

Eduard R MingazovLaboratory of Neural and Neuroendocrine Regulations, Institute of Developmental Biology RAS, 26, Vavilov St., Moscow, Russia, 119334.
Gulnara R KhakimovaLaboratory of Neural and Neuroendocrine Regulations, Institute of Developmental Biology RAS, 26, Vavilov St., Moscow, Russia, 119334.
Elena A KozinaLaboratory of Neural and Neuroendocrine Regulations, Institute of Developmental Biology RAS, 26, Vavilov St., Moscow, Russia, 119334.
Alexei E MedvedevLaboratory of Pharmacoproteomics, Institute of Biomedical Chemistry RAS, 10 Building 8, Pogodinskaya St, Moscow, Russia, 119121.
Olga A BuneevaLaboratory of Pharmacoproteomics, Institute of Biomedical Chemistry RAS, 10 Building 8, Pogodinskaya St, Moscow, Russia, 119121.
Ara S BazyanLaboratory of Neurochemical Mechanisms of Learning and Memory, Institute of Higher Nervous Activity and Neurophysiology RAS, 5A Butlerov St., Moscow, Russia, 117485.
Michael V UgrumovLaboratory of Neural and Neuroendocrine Regulations, Institute of Developmental Biology RAS, 26, Vavilov St., Moscow, Russia, 119334. michael.ugrumov@mail.ru.
Institute of Developmental Physiology · RUInstitute of Biomedical Chemistry · RUInstitute of Higher Nervous Activity and Neurophysiology · RUNational Research University Higher School of Economics · RU

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Parkinson's disease (PD) is characterized by the appearance of motor symptoms many years after the onset of neurodegeneration, which explains low efficiency of therapy. Therefore, one of the priorities in neurology is to develop an early diagnosis and preventive treatment of PD, based on knowledge of molecular mechanisms of neurodegeneration and neuroplasticity in the nigrostriatal system. However, due to inability to diagnose PD at preclinical stage, research and development must be performed in animal models by comparing the nigrostriatal system in the models of asymptomatic and early symptomatic stages of PD. In this study, we showed that despite the progressive loss of neurons in the substantia nigra at the presymptomatic and symptomatic stage, almost no change was observed in the main functional characteristics of this brain region, including dopamine (DA) uptake and release, dopamine transporter (DAT) and vesicular monoamine transporter 2 (VMAT2) expression, and activity of MAO-A and MAO-B. In the striatum of presymptomatic mice, some parameters (DA release and uptake, MAO-A activity) remained compensatory unchanged or compensatory decreased (MAO-B gene expression and activity), while others-a reduction in DA levels in tissue and extracellular space and in VMAT2 and DAT expression-manifest the functional failure. In symptomatic mice, only a few parameters (spontaneous DA release and uptake, MAO-B gene expression and activity) remained at the same level as at presymptomatic stage, while most parameters (DA level in tissue and extracellular space, DA-stimulated release, VMAT2 and DAT contents), decreased, showing decompensation, which was enhanced by increasing MAO-A activity. Thus, this study provides a comprehensive assessment of the molecular mechanisms of neuroplasticity in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine models of preclinical and clinical stages of PD, which could potentially serve as a powerful tool for translational medicine.

Indexed as

Translational Research, Biomedical1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridineAnimalsCorpus StriatumDisease Models, AnimalDopamineDopamine Plasma Membrane Transport ProteinsMaleMice, Inbred C57BLMonoamine OxidaseParkinson DiseasePotassiumRNA, MessengerSubstantia NigraVesicular Monoamine Transport Proteins1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridineDopamineDopamine Plasma Membrane Transport ProteinsMonoamine OxidasePotassiumRNA, MessengerVesicular Monoamine Transport ProteinsDopaminergic neuronsMiceMPTPNigrostriatal systemParkinson’s disease

Identifiers

PMID28456940
OpenAlexW2609499046

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.